202 related articles for article (PubMed ID: 23895653)
1. Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.
Hassler MR; Schiefer AI; Egger G
Epigenomics; 2013 Aug; 5(4):397-415. PubMed ID: 23895653
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?
Lue JK; Amengual JE; O'Connor OA
Curr Oncol Rep; 2015 Sep; 17(9):40. PubMed ID: 26141799
[TBL] [Abstract][Full Text] [Related]
3. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
4. Targeting the cancer epigenome for therapy.
Jones PA; Issa JP; Baylin S
Nat Rev Genet; 2016 Sep; 17(10):630-41. PubMed ID: 27629931
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.
Shi H; Guo J; Duff DJ; Rahmatpanah F; Chitima-Matsiga R; Al-Kuhlani M; Taylor KH; Sjahputera O; Andreski M; Wooldridge JE; Caldwell CW
Carcinogenesis; 2007 Jan; 28(1):60-70. PubMed ID: 16774933
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic targets in B- and T-cell lymphomas: latest developments.
Ribeiro ML; Sánchez Vinces S; Mondragon L; Roué G
Ther Adv Hematol; 2023; 14():20406207231173485. PubMed ID: 37273421
[TBL] [Abstract][Full Text] [Related]
7. Non-Hodgkin's lymphoma: the old and the new.
Cabanillas F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
[TBL] [Abstract][Full Text] [Related]
8. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
Zain J; O'Connor OA
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
[TBL] [Abstract][Full Text] [Related]
9. Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation.
Seitz V; Thomas PE; Zimmermann K; Paul U; Ehlers A; Joosten M; Dimitrova L; Lenze D; Sommerfeld A; Oker E; Leser U; Stein H; Hummel M
Haematologica; 2011 Jun; 96(6):863-70. PubMed ID: 21393330
[TBL] [Abstract][Full Text] [Related]
10. The therapy of non-Hodgkin's lymphomas. Introduction and overview.
Vose JM; Bierman PJ; Weisenburger DD; Armitage JO
Hematol Oncol Clin North Am; 1991 Oct; 5(5):845-52. PubMed ID: 1938757
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus is infrequently identified in non-Hodgkin's lymphomas associated with Hodgkin's disease.
Kingma DW; Medeiros LJ; Barletta J; Raffeld M; Mann RB; Ambinder RF; Jaffe ES
Am J Surg Pathol; 1994 Jan; 18(1):48-61. PubMed ID: 8279628
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Therapeutics: A New Weapon in the War Against Cancer.
Ahuja N; Sharma AR; Baylin SB
Annu Rev Med; 2016; 67():73-89. PubMed ID: 26768237
[TBL] [Abstract][Full Text] [Related]
13. [New trends in non-Hodgkin's lymphoma therapy].
Mazur G; Wróbel T; Jurczak W; Butrym A
Postepy Hig Med Dosw (Online); 2006; 60():707-21. PubMed ID: 17245320
[TBL] [Abstract][Full Text] [Related]
14. Rationale behind using valproic acid for Non-Hodgkin lymphoma: a biomolecular perspective.
Ridwansyah H; Wijaya I; Bashari MH; Kartamihardja AHS; Hernowo BS
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7486-7500. PubMed ID: 34919251
[TBL] [Abstract][Full Text] [Related]
15. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
16. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
17. Epigenetics and cancer treatment.
Kristensen LS; Nielsen HM; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
19. DNA demethylating agents and epigenetic therapy of cancer.
Mani S; Herceg Z
Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
[TBL] [Abstract][Full Text] [Related]
20. [Recent Progress of Molecular Genetic Characteristics and Prognosis of Non-Hodgkin's Lymphoma--Review].
Wang ZH; Xu M; Gu XL; Xu Z; Yu FY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):301-305. PubMed ID: 30738488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
